Swiss Pharmaceuticals & Biotech Mid-Large Cap Stocks

Novartis

Market Cap: CHF 224.1b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Roche Holding

Market Cap: CHF 260.9b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Tecan Group

Market Cap: CHF 2.3b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

Sandoz Group

Market Cap: CHF 28.2b

Develops, manufactures, and markets generic and biosimilars worldwide.

Cosmo

Market Cap: CHF 1.0b

A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.

SKAN Group

Market Cap: CHF 1.3b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

Galderma Group

Market Cap: CHF 39.6b

Operates as a dermatology company worldwide.

Bachem Holding

Market Cap: CHF 5.7b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Kuros Biosciences

Market Cap: CHF 824.7m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Lonza Group

Market Cap: CHF 40.7b

Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Dottikon ES Holding

Market Cap: CHF 3.7b

Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries.

Siegfried Holding

Market Cap: CHF 3.2b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

Idorsia

Market Cap: CHF 1.6b

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.

PolyPeptide Group

Market Cap: CHF 1.6b

Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.